Researchers at VIB, KU Leuven, the UK Dementia Research Institute and Muna Therapeutics have pinpointed a biological transition in the brain's immune cells that appears to separate people who develop dementia from those who do not, even when both carry Alzheimer's pathology. Writing in Nature Medicine, the team reports distinct cellular programs and immune-cell states linked to disease progression on one hand and resilience on the other, with microglia at the center of the difference.
The work rests entirely on human donor brain tissue, comparing older adults with cognitive decline, older adults without it, and cognitively healthy centenarians, people who passed the age of 100 with their thinking intact. That last group matters because it offers a living-tissue picture of what successful resistance looks like rather than an inference drawn from animal models. "The study, entirely based on human donor material, provides insight into one type of resilience mechanism in the progression of AD to dementia," said Prof. Bart De Strooper of KU Leuven and the VIB-KU Leuven Center for Neuroscience, a co-senior author.
The finding speaks to one of the field's most stubborn puzzles. Alzheimer's affects more than 55 million people worldwide and is defined by amyloid-beta plaques and tau tangles, yet plenty of people accumulate those hallmarks and never lose their memory. The growing view among scientists is that the answer lies less in the proteins themselves than in how surrounding brain cells react to them, and microglial activity changes sharply as the disease advances.
If specific microglial states mark the point where pathology starts to translate into cognitive loss, they become plausible targets for drugs aimed at holding the brain in its resilient configuration rather than clearing plaques after the fact. The study was funded in part by the European Research Council, and its next value lies in whether these human-derived cell states can be manipulated therapeutically.